{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:49:26Z","timestamp":1792622966546,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","award":["921082"],"award-info":[{"award-number":["921082"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-026-04933-6","type":"journal-article","created":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T16:43:05Z","timestamp":1771778585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and feasibility of intravenous fresh adipose-derived mesenchymal stem cells in secondary progressive multiple sclerosis: phase I\/IIa clinical results"],"prefix":"10.1186","volume":"17","clinical-trial-number":[{"clinical-trial-number":"irct20091127002778n1","registry":"10.18810\/irct"}],"author":[{"given":"Fahimeh Lavi","family":"Arab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forouzan","family":"Yousefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hojjat","family":"Naderi-Meshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Mirahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Faraji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Nikkhah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houshang","family":"Amiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Erfani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Ayoobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafiseh Sadat","family":"Tabasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Nikkhah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,22]]},"reference":[{"issue":"1","key":"4933_CR1","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13287-022-02786-3","volume":"13","author":"J Cui","year":"2022","unstructured":"Cui J, Jin L, Ding M, He J, Yang L, Cui S, et al. Efficacy and safety of mesenchymal stem cells in the treatment of systemic sclerosis: a systematic review and meta-analysis. Stem Cell Res Ther. 2022;13(1):118.","journal-title":"Stem Cell Res Ther"},{"key":"4933_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jneuroim.2018.11.015","volume":"328","author":"F Yousefi","year":"2019","unstructured":"Yousefi F, Lavi Arab F, Saeidi K, Amiri H, Mahmoudi M. Various strategies to improve efficacy of stem cell transplantation in multiple sclerosis: focus on mesenchymal stem cells and neuroprotection. J Neuroimmunol. 2019;328:20\u201334.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"4933_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ncl.2017.08.002","volume":"36","author":"HN Lemus","year":"2018","unstructured":"Lemus HN, Warrington AE, Rodriguez M. Multiple sclerosis: mechanisms of disease and strategies for Myelin and axonal repair. Neurol Clin. 2018;36(1):1\u201311.","journal-title":"Neurol Clin"},{"issue":"1","key":"4933_CR4","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1186\/s13287-021-02477-5","volume":"12","author":"A Shokati","year":"2021","unstructured":"Shokati A, Naser Moghadasi A, Nikbakht M, Sahraian MA, Mousavi SA, Ai J. A focus on allogeneic mesenchymal stromal cells as a versatile therapeutic tool for treating multiple sclerosis. Stem Cell Res Ther. 2021;12(1):400.","journal-title":"Stem Cell Res Ther"},{"issue":"1\u20132","key":"4933_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2013.05.010","volume":"333","author":"H Lassmann","year":"2013","unstructured":"Lassmann H. Pathology and disease mechanisms in different stages of multiple sclerosis. J Neurol Sci. 2013;333(1\u20132):1\u20134.","journal-title":"J Neurol Sci"},{"key":"4933_CR6","doi-asserted-by":"crossref","unstructured":"Yousefi F, Lavi Arab F, Nikkhah K, Amiri H, Mahmoudi M. Novel approaches using mesenchymal stem cells for curing peripheral nerve injuries. Life Sciences. Volume 221. Elsevier Inc.; 2019. pp. 99\u2013108.","DOI":"10.1016\/j.lfs.2019.01.052"},{"issue":"1","key":"4933_CR7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.schres.2014.04.040","volume":"161","author":"M Inglese","year":"2015","unstructured":"Inglese M, Petracca M. Therapeutic strategies in multiple sclerosis: A focus on neuroprotection and repair and relevance to schizophrenia. Schizophr Res. 2015;161(1):94\u2013101.","journal-title":"Schizophr Res"},{"issue":"1","key":"4933_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.biori.2017.10.005","volume":"2","author":"V Alonso-Goulart","year":"2018","unstructured":"Alonso-Goulart V, Ferreira LB, Duarte CA, de Lima IL, Ferreira ER, de Oliveira BC, et al. Mesenchymal stem cells from human adipose tissue and bone repair: a literature review. Biotechnol Res Innov. 2018;2(1):74\u201380.","journal-title":"Biotechnol Res Innov"},{"issue":"11","key":"4933_CR9","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/cns.12759","volume":"23","author":"S Dahbour","year":"2017","unstructured":"Dahbour S, Jamali F, Alhattab D, Al-Radaideh A, Ababneh O, Al\u2010Ryalat N, et al. Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy. CNS Neurosci Ther. 2017;23(11):866\u201374.","journal-title":"CNS Neurosci Ther"},{"issue":"6","key":"4933_CR10","doi-asserted-by":"publisher","first-page":"512","DOI":"10.2174\/187152709789824598","volume":"8","author":"O Katrych","year":"2009","unstructured":"Katrych O, Simone T, Azad S, Mousa S. Disease-Modifying agents in the treatment of multiple sclerosis: A review of Long-Term outcomes. CNS Neurol Disord Drug Targets. 2009;8(6):512\u20139.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"5","key":"4933_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/pnp.399","volume":"19","author":"S Binks","year":"2015","unstructured":"Binks S, Dobson R. Established, new and future disease modifying therapies for MS. Prog Neurol Psychiatry. 2015;19(5):27\u201335.","journal-title":"Prog Neurol Psychiatry"},{"key":"4933_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.msard.2017.08.003","volume":"18","author":"DD Mitsikostas","year":"2017","unstructured":"Mitsikostas DD, Goodin DS. Comparing the efficacy of disease-modifying therapies in multiple sclerosis. Mult Scler Relat Disord. 2017;18:109\u201316.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"4933_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13287-016-0319-y","volume":"7","author":"M Liu","year":"2016","unstructured":"Liu M, Zeng X, Wang J, Fu Z, Wang J, Liu M, et al. Immunomodulation by mesenchymal stem cells in treating human autoimmune disease-associated lung fibrosis. Stem Cell Res Ther. 2016;7(1):63.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"4933_CR14","doi-asserted-by":"publisher","first-page":"e2062","DOI":"10.1038\/cddis.2015.327","volume":"7","author":"F Gao","year":"2016","unstructured":"Gao F, Chiu SM, Motan DAL, Zhang Z, Chen L, Ji HL, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 2016;7(1):e2062\u20132062.","journal-title":"Cell Death Dis"},{"key":"4933_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.reth.2022.12.010","volume":"22","author":"M Teranishi","year":"2023","unstructured":"Teranishi M, Kurose T, Nakagawa K, Kawahara Y, Yuge L. Hypergravity enhances RBM4 expression in human bone marrow-derived mesenchymal stem cells and accelerates their differentiation into neurons. Regen Ther. 2023;22:109\u201314.","journal-title":"Regen Ther"},{"issue":"9","key":"4933_CR16","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1177\/13524585211062173","volume":"28","author":"D Karussis","year":"2022","unstructured":"Karussis D, Kassis I, Petrou P. Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: YES. Multiple Scler J. 2022;28(9):1324\u20136.","journal-title":"Multiple Scler J"},{"key":"4933_CR17","unstructured":"Castro-Manrreza ME, Participaci\u00f3n. de las c\u00e9lulas troncales mesenquimales en la regulaci\u00f3n de la respuesta inmune y el desarrollo de c\u00e1ncer. Vol. 73, Boletin Medico del Hospital Infantil de Mexico. Masson-Doyma Mexico, S.A.; 2016. pp. 380\u20137."},{"key":"4933_CR18","doi-asserted-by":"crossref","unstructured":"Mohamed-Ahmed S, Fristad I, Lie SA, Suliman S, Mustafa K, Vindenes H et al. Adipose-derived and bone marrow mesenchymal stem cells: A donor-matched comparison. Stem Cell Res Ther. 2018;9(1):168.","DOI":"10.1186\/s13287-018-0914-1"},{"issue":"2","key":"4933_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1136\/jnnp-2017-316271","volume":"89","author":"J Burman","year":"2018","unstructured":"Burman J, Tolf A, H\u00e4gglund H, Askmark H. Autologous Haematopoietic stem cell transplantation for neurological diseases. J Neurol Neurosurg Psychiatry. 2018;89(2):147\u201355.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4933_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.reth.2022.07.003","volume":"21","author":"A Alanazi","year":"2022","unstructured":"Alanazi A, Alassiri M, Jawdat D, Almalik Y. Mesenchymal stem cell therapy: A review of clinical trials for multiple sclerosis. Regen Ther. 2022;21:201\u20139.","journal-title":"Regen Ther"},{"key":"4933_CR21","doi-asserted-by":"crossref","unstructured":"Lavi Arab F, Yousefi F, Reza Jaafari M, Rajabian A, Dana H, Tabasi N et al. Evaluation of the immune-modulatory, anti-oxidant, proliferative, and anti-apoptotic effects of nano-silymarin on mesenchymal stem cells isolated from multiple sclerosis patients\u2019 adipose tissue sources. J Funct Foods. 2024;113:105958.","DOI":"10.1016\/j.jff.2023.105958"},{"key":"4933_CR22","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.imlet.2016.02.016","volume":"172","author":"F Yousefi","year":"2016","unstructured":"Yousefi F, Ebtekar M, Soudi S, Soleimani M, Hashemi SM. In vivo Immunomodulatory effects of adipose-derived mesenchymal stem cells conditioned medium in experimental autoimmune encephalomyelitis. Immunol Lett. 2016;172:94\u2013105.","journal-title":"Immunol Lett"},{"issue":"7","key":"4933_CR23","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1474-4422(11)70121-1","volume":"10","author":"A Uccelli","year":"2011","unstructured":"Uccelli A, Laroni A, Freedman MS. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol. 2011;10(7):649\u201356.","journal-title":"Lancet Neurol"},{"issue":"4","key":"4933_CR24","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1080\/00365513.2020.1741023","volume":"80","author":"E Adolfsson","year":"2020","unstructured":"Adolfsson E, Helenius G, Friberg \u00d6, Samano N, Fr\u00f8bert O, Johansson K. Bone marrow- and adipose tissue-derived mesenchymal stem cells from donors with coronary artery disease; growth, yield, gene expression and the effect of oxygen concentration. Scand J Clin Lab Invest. 2020;80(4):318\u201326.","journal-title":"Scand J Clin Lab Invest"},{"issue":"5","key":"4933_CR25","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1590\/S0365-05962010000500008","volume":"85","author":"S Yarak","year":"2010","unstructured":"Yarak S, Okamoto OK. C\u00e9lulas-tronco derivadas de Tecido adiposo humano: desafios atuais e perspectivas cl\u00ednicas. Bras Dermatol. 2010;85(5):647\u201356.","journal-title":"Bras Dermatol"},{"issue":"5","key":"4933_CR26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.molmed.2013.03.004","volume":"19","author":"A Haghikia","year":"2013","unstructured":"Haghikia A, Hohlfeld R, Gold R, Fugger L. Therapies for multiple sclerosis: translational achievements and outstanding needs. Trends Mol Med. 2013;19(5):309\u201319.","journal-title":"Trends Mol Med"},{"issue":"2","key":"4933_CR27","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12016-016-8552-9","volume":"52","author":"ATJ Maria","year":"2017","unstructured":"Maria ATJ, Maumus M, Le Quellec A, Jorgensen C, No\u00ebl D, Guilpain P. Adipose-Derived mesenchymal stem cells in autoimmune disorders: state of the Art and perspectives for systemic sclerosis. Clin Rev Allergy Immunol. 2017;52(2):234\u201359.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"4933_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13287-017-0540-3","volume":"8","author":"AM Robinson","year":"2017","unstructured":"Robinson AM, Rahman AA, Miller S, Stavely R, Sakkal S, Nurgali K. The neuroprotective effects of human bone marrow mesenchymal stem cells are dose-dependent in TNBS colitis. Stem Cell Res Ther. 2017;8(1):87.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"4933_CR29","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13287-024-03713-4","volume":"15","author":"ZT Ahmed","year":"2024","unstructured":"Ahmed ZT, Zain Al-Abeden MS, Al Abdin MG, Muqresh MA, Al Jowf GI, Eijssen LMT, et al. Dose-response relationship of MSCs as living Bio-drugs in HFrEF patients: a systematic review and meta-analysis of RCTs. Stem Cell Res Ther. 2024;15(1):165.","journal-title":"Stem Cell Res Ther"},{"key":"4933_CR30","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.bbrc.2023.08.041","volume":"678","author":"H Babaei","year":"2023","unstructured":"Babaei H, Kheirollah A, Ranjbaran M, Sarkaki A, Adelipour M. Dose-dependent neuroprotective effects of adipose-derived mesenchymal stem cells on amyloid \u03b2-induced alzheimer\u2019s disease in rats. Biochem Biophys Res Commun. 2023;678:62\u20137.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"4933_CR31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13041-021-00787-6","volume":"14","author":"H Magota","year":"2021","unstructured":"Magota H, Sasaki M, Kataoka-Sasaki Y, Oka S, Ukai R, Kiyose R, et al. Repeated infusion of mesenchymal stem cells maintain the condition to inhibit deteriorated motor function, leading to an extended lifespan in the SOD1G93A rat model of amyotrophic lateral sclerosis. Mol Brain. 2021;14(1):76.","journal-title":"Mol Brain"},{"issue":"3","key":"4933_CR32","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s11481-018-09832-z","volume":"14","author":"MC Gonz\u00e1lez-Oria","year":"2019","unstructured":"Gonz\u00e1lez-Oria MC, M\u00e1rquez-Coello M, Gir\u00f3n-Ortega JA, Argente J, Moya M, Gir\u00f3n-Gonz\u00e1lez JA. Monocyte and lymphocyte activation and regulation in multiple sclerosis Patients. Therapy effects. J Neuroimmune Pharmacol. 2019;14(3):413\u201322.","journal-title":"J Neuroimmune Pharmacol"},{"key":"4933_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.clim.2017.06.006","volume":"181","author":"M Spadaro","year":"2017","unstructured":"Spadaro M, Montarolo F, Perga S, Martire S, Brescia F, Malucchi S, et al. Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10 years in responder multiple sclerosis patients. Clin Immunol. 2017;181:83\u20138.","journal-title":"Clin Immunol"},{"issue":"1\u20132","key":"4933_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jns.2012.05.036","volume":"319","author":"P Praksova","year":"2012","unstructured":"Praksova P, Stourac P, Bednarik J, Vlckova E, Mikulkova Z, Michalek J. Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations. J Neurol Sci. 2012;319(1\u20132):18\u201323.","journal-title":"J Neurol Sci"},{"issue":"1","key":"4933_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12974-017-0892-8","volume":"14","author":"KM Danikowski","year":"2017","unstructured":"Danikowski KM, Jayaraman S, Prabhakar BS. Regulatory T cells in multiple sclerosis and myasthenia Gravis. J Neuroinflammation. 2017;14(1):117.","journal-title":"J Neuroinflammation"},{"issue":"7","key":"4933_CR36","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/ncpneuro0832","volume":"4","author":"AL Zozulya","year":"2008","unstructured":"Zozulya AL, Wiendl H. The role of regulatory T cells in multiple sclerosis. Nat Clin Pract Neurol. 2008;4(7):384\u201398.","journal-title":"Nat Clin Pract Neurol"},{"key":"4933_CR37","doi-asserted-by":"crossref","unstructured":"Sinha S, Boyden AW, Itani FR, Crawford MP, Karandikar NJ. CD8\u2009+\u2009T-Cells as immune regulators of multiple sclerosis. Front Immunol. 2015;6:619.","DOI":"10.3389\/fimmu.2015.00619"},{"issue":"7","key":"4933_CR38","doi-asserted-by":"publisher","first-page":"a018341","DOI":"10.1101\/cshperspect.a018341","volume":"5","author":"OJ Harrison","year":"2013","unstructured":"Harrison OJ, Powrie FM, Regulatory T. Cells and immune tolerance in the intestine. Cold Spring Harb Perspect Biol. 2013;5(7):a018341\u2013018341.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"6","key":"4933_CR39","doi-asserted-by":"publisher","first-page":"e21386","DOI":"10.1371\/journal.pone.0021386","volume":"6","author":"D Dalla Libera","year":"2011","unstructured":"Dalla Libera D, Di Mitri D, Bergami A, Centonze D, Gasperini C, Grasso MG, et al. T regulatory cells are markers of disease activity in multiple sclerosis patients. PLoS ONE. 2011;6(6):e21386.","journal-title":"PLoS ONE"},{"issue":"4","key":"4933_CR40","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1159\/000448180","volume":"43","author":"L Frese","year":"2016","unstructured":"Frese L, Dijkman PE, Hoerstrup SP. Adipose Tissue-Derived stem cells in regenerative medicine. Transfus Med Hemotherapy. 2016;43(4):268\u201374.","journal-title":"Transfus Med Hemotherapy"},{"issue":"3","key":"4933_CR41","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/ana.24113","volume":"75","author":"EL Feldman","year":"2014","unstructured":"Feldman EL, Boulis NM, Hur J, Johe K, Rutkove SB, Federici T, et al. Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann Neurol. 2014;75(3):363\u201373.","journal-title":"Ann Neurol"},{"issue":"1","key":"4933_CR43","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/TA.0000000000000681","volume":"79","author":"AV Gore","year":"2015","unstructured":"Gore AV, Bible LE, Song K, Livingston DH, Mohr AM, Sifri ZC. Mesenchymal stem cells increase T-regulatory cells and improve healing following trauma and hemorrhagic shock. J Trauma Acute Care Surg. 2015;79(1):48\u201352.","journal-title":"J Trauma Acute Care Surg"},{"issue":"8","key":"4933_CR44","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1093\/brain\/awg182","volume":"126","author":"F Bagnato","year":"2003","unstructured":"Bagnato F. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain. 2003;126(8):1782\u20139.","journal-title":"Brain"},{"issue":"6","key":"4933_CR45","doi-asserted-by":"publisher","first-page":"850","DOI":"10.4103\/1673-5374.158352","volume":"10","author":"A Castorina","year":"2015","unstructured":"Castorina A, Szychlinska M, Marzagalli R, Musumeci G. Mesenchymal stem cells-based therapy as a potential treatment in neurodegenerative disorders: is the escape from senescence an answer? Neural Regen Res. 2015;10(6):850.","journal-title":"Neural Regen Res"},{"issue":"8","key":"4933_CR46","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1002\/stem.2651","volume":"35","author":"R Volkman","year":"2017","unstructured":"Volkman R, Offen D. Concise review: mesenchymal stem cells in neurodegenerative diseases. Stem Cells. 2017;35(8):1867\u201380.","journal-title":"Stem Cells"},{"issue":"2 suppl","key":"4933_CR47","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1590\/0001-3765201520140619","volume":"87","author":"GD COLPO","year":"2015","unstructured":"COLPO GD, ASCOLI BM, WOLLENHAUPT-AGUIAR B, PFAFFENSELLER B, SILVA EG, CIRNE-LIMA EO, et al. Mesenchymal stem cells for the treatment of neurodegenerative and psychiatric disorders. Acad Bras Cienc. 2015;87(2 suppl):1435\u201349.","journal-title":"Acad Bras Cienc"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-026-04933-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-04933-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-04933-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:03:35Z","timestamp":1774623815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13287-026-04933-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,22]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4933"],"URL":"https:\/\/doi.org\/10.1186\/s13287-026-04933-6","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,22]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study, entitled\n                      \u201c\n                      Study of autologous adipose-derived mesenchymal stem cells transplantation in the treatment of multiple sclerosis in secondary progressive phase,\n                      \u201d\n                      was approved by the Ethics Committee of Mashhad University of Medical Sciences, Mashhad, Iran (IR.MUMS.REC.1394.633; Date of approval: August 20, 2015). The study was conducted in accordance with the Declaration of Helsinki. All patients or their representatives signed written informed consent forms before participation. Additionally, the clinical trial was registered in the Iranian Registry of Clinical Trials (Reference: IRCT20091127002778N1 at October 1, 2018).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients provided written informed consent for publication of their data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}